Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain ...
Q4 GAAP revenues of $596.9 million, up 6.2% from Q4 2024. For fiscal 2025, GAAP revenues were $2,321.7 million, up 5.4% year over year.Organic ASV was $2,370.9 million at August 31, 2025, up 5.7% year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback